Phase 1bData readout

DNL921 (Abeta TransportVehicle)

Alzheimer's Disease

DNLIDenali Therapeutics

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: DNL921 (Abeta TransportVehicle)
Development stage: Phase 1b
Event type: Data readout
Indication: Alzheimer's Disease

Research summary

What is being tracked?

This catalyst tracks a Phase 1b data readout for DNL921 (Abeta TransportVehicle) in Alzheimer's Disease. The expected timing is based on the latest available company guidance and may change.

Development notes

02/26/26:- IND-enabling work ongoing for DNL921 ATV:Abeta program in Alzheimer's disease. 05/07/26:- On track to submit DNL921 regulatory filing in H1 2026 to begin clinical development. 08/06/26:- DNL921 entered Ph1/1b; safety and proof-of-concept data expected in 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

DNL921 (Abeta TransportVehicle)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

AVLAYAH™ (tividenofusp alfa) (DNL310)

BIIB122 (DNL151)

TAK-594/DNL593 (PTV:PGRN)

DNL628 (Tau-Targeting Oligonucleotide)